High Risk for Bleeding in Older Patients Anticoagulated for Venous Thromboembolism
Researchers sought to determine bleeding risks for older patients treated with anticoagulation with vitamin K antagonists for the treatment of VTE.
Researchers sought to determine bleeding risks for older patients treated with anticoagulation with vitamin K antagonists for the treatment of VTE.
Researchers sought to determine whether ABO blood type may impact the risk of developing VTE in patients with cancer.
Researchers sought to determine whether using a D-dimer assay would help determine whether patients require extended treatment for VTE.
Researchers sought to determine CV event occurrence in patients treated with immune checkpoint inhibitors and assess the accuracy of diagnosis by ICD code compared with adjudication using established definitions.
Researchers sought to compare oral apixaban and subcutaneous dalteparin for treating patients with cancer-related venous thromboembolism.
Researchers sought to determine whether immune checkpoint inhibitors would increase risk of VTE compared with chemotherapy among patients with cancer.
Researchers sought to determine whether there was a link between abnormal menstrual bleeding and treatment with anticoagulants for VTE.
Recommendations for venous thromboembolism prophylaxis in patients with cancer were discussed in an oral session at JADPRO Live 2022.
Patients with chronic lymphocytic leukemia or monoclonal B-cell lymphocytosis have an increased risk of venous thromboembolism, a study suggests.
Researchers sought to determine whether the addition of IPC to thromboprophylaxis for prevention of VTE is based on sound evidence.